Gene-directed enzyme prodrug therapy

Bioconjugate Chemistry

Volumn 9, Issue 1, 1998, Pages 4-22

  Niculescu Duvaz, Ion ^a   Spooner, Robert ^a   Marais, Richard ^a   Springer, Caroline J ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENZYME-PRODRUG THERAPIES;

GENE THERAPY;

ANIMALIA;

EID: 0031983448     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc970116t     Document Type: Review

References (156)

1. W. W. Zhang, T. Fujiwara, E. A. Grimm, and J. A. Roth (1995) Advances in cancer gene therapy. Adv. Pharmacol. 12, 289-341.
2. R. E. Christoffersen and J. J. Marr (1995) Ribozymes as human therapeutic agents. J. Med. Chem. 38, 2023-2037.
3. B. P. Sorrentino, C. J. Brandt, D. Bodine, M. Gottesman, I. Pastan, A. Cline, and A. W. Nienhuis. (1992) Selection of drug-resistant bone marrow cells in vivo after retroviral transfer of human MDR1. Science 257, 99-103.
4. G. Wang, C. Weiss, P. Sheng, and E. Bresnick. (1996) Retrovirus mediated transfer of the human O6-methylguanine-DNA methyl transferase gene into a murine hematopoietic stem cell line and resistance to the toxic effects of certain alkylating agents. Biochem. Pharmacol. 51, 1221-1228.
5. J. E. Reese, O. N. Koc, K. M. Lee, L. Liu, J. A. Allay, W. P. Phillips, and S. L. Gerson (1996) Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea. Proc. Natl. Acad. Sci. U.S.A. 93, 14088-14093.
6. S. Letourneau, M. Greenbaum, and D. Cournoyer. (1996) Retrovirus-mediated gene transfer of rat glutathione-S-transferase Yc confers in vitro resistance to alkylating agents in human leukemia cells and in clonogenic mouse hematopoietic progenitor cells. Hum. Gene Ther. 7, 831-840.
7. G. Bridgewater, C. J. Springer, R. Knox, N. Minton, P. Michael, and M. Collins. (1995) Expression of the bacterial nitroreductase enzyme in mammalian cells renders them selectively sensitive to killing by the prodrug CB1954. Eur. J. Cancer 31A, 2362-2370.
8. R. Marais, R. A. Spooner, Y. Light, J. Martin, and C. J. Springer (1996) Gene-directed enzyme prodrug therapy with a mustard prodrug/carboxypeptidase G2 combination. Cancer Res. 56, 4735-4742.
9. B. E. Huber, C. A. Richards, and E. A. Austin (1995) VDEPT; An enzyme/prodrug gene therapy approach for the treatment of metastatic colorectal cancer. Adv. Drug Delivery Rev. 17, 279-292.
10. R. G. Vile, R. M. Diaz, N. Miller, A. Tuszyanski, and S. G. Russell (1995) Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 214, 307-313.
11. E. J. Kremer and M. Perricaudet (1995) Adenovirus and AAV mediated gene transfer. Br. Med. Bull. 51, 31-44.
12. J. C. Glorioso, N. A. DeLuca, and D. J. Fink (1995) Development and application of herpes simplex virus vectors for human gene therapy. Annu. Rev. Microbiol. 49, 675-710.
13. F. Ledley (1995) Nonviral gene therapy: the promise of genes as pharmaceutical products. Hum. Gene Ther. 6, 1129-1144.
14. G. P. Behr (1994) Gene transfer with synthetic cationic amphiphiles: prospects for gene therapy. Bioconjugate Chem. 5, 382-389.
15. M. S. Wadha, W. T. Collard, R. C. Adami, D. L. McKenzie, and K. G. Rice (1997) Peptide-mediated gene delivery: influence of peptide structure on gene expression. Bioconjugate Chem. 8, 81-88.
16. R. A. Spooner, M. P. Deonarain, and A. A. Epenetos (1995) DNA vaccination for cancer treatment. Gene Ther. 2, 173-180.
17. S. W. Ebbinghaus, N. Vigneswaran, C. R. Miller, R. A. Chee-Awai, C. A. Mayfield, D. T. Curiel, and D. M. Miller (1996) Efficient delivery of triplex forming oligonucleotides to tumour cells by adenovirus-polylysine complexes. Gene Ther. 3, 287-297.
18. M. E. Fox, M. J. Lemmon, M. L. Mauchline, T. O. Davis, A. J. Giaccia, N. P. Minton, and J. M. Brown (1996) Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther. 3, 173-178.
19. S. J. Russell (1994) Replicating vectors for gene therapy of cancers: risks, limitations and prospects. Eur. J. Cancer 30A, 1165-1171.
20. S. J. Russell, A. Brandenburger, C. L. Flemming, M. K. Collins, and J. Rommelaere (1992) Transformation-dependent expression of interleukin genes delivered by a recombinant parvovirus. J. Virol. 66, 2821-2828.
21. X. S. Wang, M. C. Yoder, S. Z. Zhou, and A. Srivastava (1995) Parvovirus B19 promoter at map unit 6 confers autonomous replication competence and erythroid specificity to adeno-associated virus 2 in primary human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 92, 12416-12420.
22. K. W. Culver (1996) The role of herpes simplex thymidine kinase gene transfer in the drug treatment of brain tumors. CNS Drugs 6, 1-11.
23. E. Benaim and B. P. Sorrentino (1996) Gene therapy in pediatric oncology. Invest. New Drugs 14, 87-99.
24. F. Kanai, Y. Shiratori, H. Wakimoto, Y. Kanegae, I. Saito, H. Nakabayashi, T. Tamaoki, T. Tanka, K. H. Lan, N. Kato, S. Shiina, and M. Omata (1996) Gene therapy for α-fetoprotein producing human hepatoma cells by adenovirus mediated transfer of the herpes simplex virus thymidine kinase gene. Hepatology 23, 1359-1368.
25. Y. Takeuchi, F. L. Cosset, P. J. Lachmann, H. Okada, R. A. Weiss, and M. K. Collins (1994) Type-C retrovirus inctivation by human complement is determinated by both the viral genome and the producer cell. J. Virol. 68, 8001-8007.
26. R. P. Rother, W. L. Fodor, J. P. Springhorn, C. W. Birks, E. Setter, M. S. Sandrin, S. P. Squinto, and S. A. Rollins (1995) A novel mechanism of retrovirus inactivation in human serum mediated by anti-α-galactosyl natural antibody. J. Exp. Med. 182, 1345-1355.
27. Y. Takeuchi, C. D. Porter, K. M. Strahan, A. F. Preece, K. Gustafsson, F. L. Cosset, R. A. Weiss, and M. K. Collins (1996) Sensitization of cells and retroviruses to human serum by (α1-3) galactosyl transferase. Nature 379, 85-88.
28. F.-L. Cosset, Y. Takeuchi, J. L. Battini, R. A. Weiss, M. K. Collins, and S. J. Russell (1995a) High-titer packaging cells producing recombinant retroviruses. J. Virol. 69, 7430-7436.
29. R. J. Rigg, J. Chen, J. S. Dando, S. P. Forestell, I. Plavec, and E. Bohnlein (1996) A novel human amphotropic packaging cell line: high titer, complement resistance, and improved safety. Virology 218, 290-295.
30. D. W. Russell, S. M. Berger, and A. D. Miller (1995) The effects of human serum and cerebrospinal fluid on retroviral vectors and packaging cell lines. Hum. Gene Ther. 5, 635-641.
31. K. Shimizu, Y. Miyao, M. Tamura, H. Kishima, M. Okhawa, E. Mabuchi, M. Yamada, T. Hayakawa, and K. Ikenaka (1995) Infectious retrovirus is inactivated by serum but not by cerebrospinal fluid or fluid from the tumor bed in patients with malignant glioma. Jpn. J. Cancer Res. 86, 1010-1013.
32. R. Weiss (1993) In The Retroviridae (J. Levy, Ed.) Vol. 2, pp 1-108, Plenum Press, New York.
33. P. Roux, P. Jeanteur, and M. Piechaczyk (1989) A versatile and potentially general approach to the targeting of specific cell types by recombinant retroviruses. Proc. Natl. Acad. Sci. U.S.A. 86, 9079-9083.
34. M. Etienne-Julan, P. Roux, S. Carillo, P. Jeanteur, and M. Piechaczyk (1992) The efficiency of cell targeting by recombinant retroviruses depends on the nature of the receptor and the composition of the artificial cell-virus linker. J. Gen. Virol. 73, 3251-3255.
35. H. Neda, C. Wu, and G. Y. Wu (1991) Chemical modification on a ecotropic murine leukemia virus results in redirection of its target specificity. J. Biol. Chem. 266, 14143-14146.
36. J. Calafat, H. Janssen, P. Demant, J. Hilgers, and J. Zavada (1983) Specific selection of host cell glycoproteins during assembly of murine leukemia virus and vesicular stomatitis virus: presence of H-2, Pgp-1 and t-200 glycoproteins on the envelopes of these virus particles. J. Gen. Virol. 64, 1241-1253.
37. J. A. T. Young, P. Bates, K. Willert, and H. E. Varmus (1990) Efficient incorporation of human CD4 protein into avian leukosis virus particle. Science 250, 1421-1423.
38. L. O. Arthur, J. V. J. Bess, R. R. Sowder II, R. E. Benveniste, D. L. Mann, J. C. Chermann, and L. E. Henderson (1992) Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science 258, 1935-1938.
39. D. W. Russell, R. E. Hawkins, and G. Winter (1993) Retroviral vectors displaying functional antibody fragments. Nucleic Acids Res. 21, 1081-1085.
40. T.-H. T. Chu, I. Martinez, W. Sheay, and R. Dornburg (1994) Cell targeting with retroviral particles containing antibody-envelope fusion proteins. Gene Ther. 1, 292-299.
41. N. V. Somia, M. Zoppe, and I. M. Verma (1995) Generation of targeted retroviral vectors by using single-chain variable fragment: an approach to in vivo gene therapy. Proc. Natl. Acad. Sci. U.S.A. 92, 7570-7574.
42. T.-H. T. Chu and R. Dornburg (1995) Retroviral vector particles displaying the antigen-binding site of an antibody enable cell-type-specific gene transfer. J. Virol. 69, 2659-2663.
43. S. Valsesia-Wittman, A. Drynda, G. Deleage, M. Aumailley, J.-M. Heard, O. Danos, G. Verdier, and F. L. Cosset (1994) Modifications in the binding domain of avian retrovirus envelope protein to redirect the host range of retroviral vectors. J. Virol. 68, 4609-4619.
44. N. Kasahara, A. M. Dozy, and Y. W. Kan (1994) Tissue-specific targeting of retroviral vectors through ligand-receptor interactions. Science 266, 1373-1376.
45. K. Han, N. Kasahara, and Y. W. Kan (1995) Ligand-directed retroviral targeting of human breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 92, 9747-9751.
46. T. Matano, T. Odawara, A. Iwamoto, and H. Yoshikura (1995) Targeted infection of a retrovirus bearing a CD4-Env chimera into human cells expressing human immunodeficiency virus type 1. J. Gen. Virol. 76, 3165-3169.
47. F.-L. Cosset, F. J. Morling, Y. Takeuchi, J. L. Battini, R. A. Weiss, M. K. Collins, and S. J. Russell (1995b) Retroviral retargeting by envelopes expressing an N-terminal binding domain. J. Virol. 69, 6314-6322.
48. S. Valesia-Wittman, F. J. Morling, B. H. K. Nilson, Y. Takeuchi, S. J. Russell, and F.-L. Cosset (1996) Improvement of retroviral retargeting by using amino acid spacers between an additional binding domain and the N-terminus of Moloney leukemia virus SU. J. Virol. 70, 2059-2064.
49. M. Marin, D. Noel, S. Valesia-Wittman, F. Brockly, M. Etienne-Julan, S. Russell, F.-L. Cosset, and M. Piechaczyk (1996) Targeted infection of human cells via Major Histocompatibility Complex Class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins. J. Virol. 70, 2957-2962.
50. B. H. Nilson, F. J. Morling, L.-F. Cosset, and S. J. Russell (1996) Targeting of retroviral vectors through protease-substrate interactions. Gene Ther. 3, 280-286.
51. D. Kabat (1995) Targeting retroviral vectors to specific cells. Science 269, 417.
52. V. N. Krasnykh, G. V. Mikheeva, J. T. Douglas, and D. T. Curiel (1996) Generation of recombinant adenovirus vectors with modified fibers for altering viral tropism. J. Virol. 70, 6839-6846.
53. S. I. Michael, J. S. Hong, D. T. Curiel, and J. A. Engler (1995) Addition of a short peptide to the adenovirus fiber protein. Gene Ther. 2, 660-668.
54. J. S. Hong and J. A. Engler (1996) Domains required for assembly of adenovirus type 2 fiber trimers. J. Virol. 70, 7071-7078.
55. B. A. Huber, C. A. Richards, and T. A. Krenitsky (1991) Retroviral-mediated gene therapy for the treatment of hepatocellular carcinoma: An innovative approach for cancer therapy. Proc. Natl. Acad. Sci. U.S.A. 88, 8039-8043.
56. A. Ido, K. Nakata, Y. Kato, K. Nakao, K. Murata, M. Fujita, N. Ishii, T. Tamaoki, H. Shiku, and S. Nagataki (1995) Gene therapy for hepatoma cells using a retrovirus vector carrying herpes simplex virus thymidine kinase under the control of human α-fetoprotein gene promoter. Cancer Res. 55, 3105-3109.
57. N. K. Wills, W. M. Huang, M. P. Harris, T. Machemer, D. C. Maneval, and R. J. Gregory (1995) Gene-therapy for hepatocellular carcinoma; chemosensitivity conferred by adenovirus mediated transfer of the HSV-1 thymidine kinase gene. Cancer Gene Ther. 2, 191-197.
58. S. Kaneko, P. Hallenbeck, T. Kotani, H. Nabayashi, G. McGarrity, T. Tamaoki, W. F. Anderson, and Y. L. Chiang (1995) Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res. 55, 5283-5287.
59. H. Su, J. C. Chiang, S. M. Xu, and Y. W. Kan (1996) Selective killing of AFP-positive cells by adeno-associated virus transfer of the herpes simplex virus thymidine kinase gene. Hum. Gene Ther. 7, 463-470.
60. R. I. Garver Jr., K. T. Goldsmith, B. Rodu, P. C. Hu, and D. T. Curiel (1994) Strategy for achieving selective killing of carcinomas. Gene Ther. 1, 46-50.
61. S. C. Ko, J. Cheong, C. Kao, A. Gotoh, T. Shirakawa, R. A. Sikes, G. Karsenty, and L. K. W. Chung (1996) Osteocalcin promoter-based toxic gene therapy for the treatment of osteosarcoma in experimental models. Cancer Res. 56, 4614-4619.
62. T. Kumagai, Y. Tanio, T. Osaki, S. Hosoe, Y. Tachibana, K. Veno, T. Kijima, T. Horai, and T. Kishimoto (1996) Eradication of Myc-overexpressing small cell lung cancer cells transfected with herpes simplex virus thymidine kinase gene containing Myc-Max response elements. Cancer Res. 56, 354-358.
63. T. Osaki, Y. Tanio, I. Tachibana, S. Hosoe, T. Kumagai, I. Kawase, S. Oikawa, and T. Kishimoto (1994) Gene therapy for carcinoembryonic antigen-producing cancer cells by cell type-specific expression of herpes simplex virus thymidine kinase gene. Cancer Res. 54, 5258-5261.
64. J. M. DiMaio, B. M. Clary, D. F. Via, E. Coveney, T. N. Pappas, and H. K. Lyerly (1994) Directed enzyme pro-drug gene therapy for pancreatic cancer in vivo. Surgery 116, 205-213.
65. T. Tanaka, F. Kanai, S. Okabe, Y. Yoshida, H. Wakimoto, H. Hamada, Y. Shiratori, K. Lan, M. Ishitobi, and M. Omata (1996) Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen producing human gastric carcinoma cells in vitro. Cancer Res. 56, 1341-1345.
66. C. A. Richards, E. A. Austin, and B. E. Huber (1995) Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum. Gene Ther. 6, 881-893.
67. J. M. Bosher, T. Williams, and H. C. Hurst (1995) The developmentally regulated transcription factor AP-2 is involved in c-erbB2 overexpression in human mammary carcinoma. Proc. Natl. Acad. Sci. U.S.A. 92, 744-747.
68. D. P. Hollywood and H. C. Hurst (1993) A novel transcription factor, OB2-1, is required for overexpression of the protooncogene c-erbB-2 in mammary tumour lines. EMBO J. 12, 2369-2375.
69. J. D. Harris, A. A. Gutierrez, H. C. Hurst, K. Sikora, and N. R. Lemoine (1994) Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther. 1, 170-175.
70. Y. Manome, M. Abe, M. F. Hagen, H. A. Fine, and D. W. Kufe (1994) Enhancer sequences of the DF3 gene regulate expression of the herpes simplex virus thymidine kinase gene and confer sensitivity of human breast cancer. Cancer Res. 54, 5408-5413.
71. L. Chen, D. Chen, Y. Manome, Y. Dong, H. A. Fine, and D. W. Kufe (1995) Breast cancer selective gene expression and therapy mediated by recombinant adenoviruses controling the DF3/MUCI promoter. J. Clin. Invest. 96, 2775-2782.
72. F. L. Moolten and J. M. Wells (1990) Curability of tumors bearing Herpes virus thymidine kinase genes transferred by retroviral vectors. J. Natl. Cancer Inst. 82, 297-300.
73. R. G. Vile and I. R. Hart (1993a) In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 53, 962-967.
74. R. G. Vile and I. R. Hart (1993b) Use of tissue-specific expression of the herpes simplex virus thymidine kinase gene to inhibit growth of established murine melanomas following direct intratumoral injection of DNA. Cancer Res. 53, 3860-3864.
75. B. W. Hughes, A. H. Wells, Z. Bebok, V. K. Gadi, R. I. Garver Jr., W. B. Parker, and E. J. Sorscher(1995) Bystander killing of melanoma cells using the human tyrosinase promoter to express the E. Coli purine nucleoside phosphorylase gene. Cancer Res. 55, 3339-3345.
76. I. R. Hart (1996) Tissue-specific promoters in targeting systemically delivered gene therapy. Semin. Oncol. 23, 154-158.
77. M. E. Black, T. G. Newcomb, H. M. Wilson, and L. A. Loeb (1996) Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93, 3525-3529.
78. R. Vile, J. A. Nelson, S. Castledon, H. Chang, and I. Hart (1994) Systemic gene therapy of murine melanoma using tissue-specific expression of HSV-TK gene involves an immune response. Cancer Res. 54, 6228-6234.
79. S. Gagandeep, R. Brew, B. Green, S. E. Christmas, D. Klatzmann, G. J. Poston, and A. R. Kinsella (1996) Prodrug-activated gene therapy: Involvement of an immunological component in the "bystander effect". Gene Ther. 3, 83-88.
80. M. Caruso, Y. Panis, S. Gagandeep, D. Houssin, J. L. Salzmann, and D. Klatzmann (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc. Natl. Acad. Sci. U.S.A. 90, 7024-7028.
81. D. R. Averett, G. A. Kozalka, J. A. Fyfe, G. B. Roberts, D. J. M. Purifoy, and T. A. Krenitsky (1991) 6-methoxypurine arabinoside as a selective and potent inhibitor of varicella-zoster virus. Antimicrob. Agents Chemother. 35, 851-857.
82. G. B. Elion (1980) The chemotherapeutic exploitation of virus-specified enzymes. Adv. Enzymes Regul. 18, 53-66.
83. H. S. Allaudeen, J. Descamps, R. K. Sehgal, and J. J. Fox (1982) Selective inhibition of DNA replication in herpes simplex virus infected cells by 1-(2′-deoxy-2′-fluoro-β-D-arabinofuranosyl)-5-iodocytosine. J. Biol. Chem. 257, 11879-11882.
84. H. Wallace, A. R. Clarke, D. J. Harrison, M. L. Hooper, and J. O. Bishop (1996) Ganciclovir-induced ablation of non-proliferating thyrocytes expressing herpes virus thymidine kinase occurs by p53-independent apoptosis. Oncogene 13, 55-61.
85. J. G. Tjuvajev, R. Finn, K. Watanabe, R. Joshi, T. Oku, J. Kennedy, B. Beattie, J. Koutcher, S. Larson, and R. G. Blasberg (1996) Noninvasive imaging of herpes simplex virus thymidine kinase gene transfer and expression: A potential method for monitoring clinical gene therapy. Cancer Res. 56, 4087-4095.
86. M. G. Sacco, L. Mangiovini, A. Villa, P. Macchi, O. Barbieri, M. C. Sacchi, E. Monteggia, V. Fasolo, P. Vezzoni, and L. Clerici (1995) Local regression of breast tumors following intramammary ganciclovir administration in double transgenic mice expressing neu oncogene and herpes simplex virus thymidine kinase. Gene Ther. 2, 493-497.
87. (1995) Clinical protocol list. Cancer Gene Ther. 2, 225-234.
88. F. L. Moolten (1986) Tumor chemosensitivity conferred by inserted Herpes thymidine kinase genes: Paradigm for a prospective cancer control strategy. Cancer Res. 46, 5276-5281.
89. F. L. Moolten, B. K. Vonderhaar, and P. J. Mroz (1996) Transduction of the herpes thymidine kinase gene into premalignant murine mammary epithelial cells renders subsequent breast cancers responsive to ganciclovir therapy. Hum. Gene Ther. 7, 1197-1204.
90. E. Borelli, R. Heyman, M. Hsi, and R. M. Evans (1988) Targeting of an inducible toxic phenotype in animal cell. Proc. Natl. Acad. Sci. U.S.A. 85, 7572-7576.
91. D. K. Hoganson, R. K. Batra, J. C. Olsen, and R. C. Boucher (1996) Comparison of the effect of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 56, 1315-1323.
92. S. Kuriyama, T. Nakatani, K. Masui, T. Sakamoto, K. Tominaga, M. Yoshikawa, H. Fukui, K. Ikenaka, and T. Tsujii (1996) Evaluation of prodrugs ability to induce effective ablation of cells transduced with viral thymidine kinase gene. Anticancer Res. 16, 2623-2628.
93. K. W. Culver, Z. Ram, S. Wallbridge, H. E. H. Oldfield, and M. R. Blaese (1992) In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 256, 1550-1552.
94. D. Barba, J. Hardin, J. Ray, and F. H. Gage (1993) Thymidine kinase-mediated killing of rat brain tumors. J. Neurosurg. 79, 729-735.
95. D. Barba, J. Hardin, M. Sadelain, and F. H. Gage (1994) Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc. Natl. Acad. Sci. U.S.A. 91, 4348-4352.
96. S. H. Chen, H. D. Shine, J. C. Goodman, R. G. Grossman, and S. L. C. Woo (1994) Gene therapy for brain tumors: Regression of experimental gliomas by adenovirus-mediated gene transfer in vivo. Proc. Natl. Acad. Sci. U.S.A. 91, 3054-3057.
97. Z. Ram, K. W. Culver, S. Walbridge, R. M. Blaese, and E. H. Oldfield (1993) In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88.
98. S. J. Tapscott, A. D. Miller, J. M. Olson et al. (1994) Gene therapy of 9L rat gliosarcoma tumors by transduction with selectable genes does not require drug selection. Proc. Natl. Acad. Sci. U.S.A. 91, 8185-8189.
99. N. G. Rainov, C. M. Kramm, K. Aboody-Guterman, M. Chase, K. Ueki, D. N. Loius, G. R. Harsh IV, E. A. Chiocca, and X. O. Breakefield (1996) Retrovirus-mediated gene therapy of experimental brain neoplasms using the herpes simplex virus-thymidine kinase/ganciclovir paradigm. Cancer Gene Ther. 3, 99-106.
100. A. Maron, T. Gustin, A. Le Roux, I. Mottet, J. F. Dedieu, J. P. Brion, R. Demeure, M. Perricaudet, and J. N. Octave (1996) Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long time follow-up by magnetic resonance imaging. Gene Ther. 3, 315-322.
101. V. Cool, B. Pirotte, C. Gerard, J. L. Dargent, N. Baudson, M. Levivier, S. Goldman, J. Hildebrandt, J. Brotchi, and T. Velu (1996) Curative potential of herpes simplex virus thymidine kinase gene transfer in rats with 9L gliosarcoma. Hum. Gene Ther. 7, 627-635.
102. A. J. P. E. Vincent, R. Vogels, G. V. Someren, M. C. Esandi, J. L. Noteboom, C. J. J. Avezaat, C. Vecht, D. W. V. Bekkum, D. Valerio, A. Bout, and P. M. Hoogerbrugge (1996) Herpes simplex virus thymidine kinase gene therapy for rat malignant brain tumors. Hum. Gene Ther. 7, 197-205.
103. M. E. Rosenfeld, M. Wang, G. P. Siegal, R. D. Alvarez, G. Mikheeva, V. Krasnykh, and D. T. Curiel (1996) Adenoviral-mediated delivery of herpes simplex virus thymidine kinase results in tumor reduction and prolonged survival in SCID mouse model of human ovarian carcinoma. J. Mol. Med. 74, 455-462.
104. D. Yee, S. E. McGuire, N. Brunner, T. W. Kozelsky, D. C. Allred, S. H. Chen, and S. L. C. Woo (1996) Adenovirus-mediated gene transfer of herpes simplex virus thymidine kinase in an ascites model of human breast cancer. Hum. Gene Ther. 7, 1251-1257.
105. J. A. Eastham, S. H. Chen, I. Sehgal, G. Yang, T. L. Timme, S. J. Hall, S. L. C. Woo, and T. C. Thompson (1996) Prostate cancer gene therapy: Herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Ther. 7, 515-523.
106. M. MacCoss and M. J. Robins (1990) In Chemistry of Antitumour Agents (D. E. V. Wilman, Ed.) pp 261-298, Blackie & Son Ltd., Chapman & Hall, London, New York.
107. D. S. Martin (1987) In Metabolism and Action of Anti-cancer Drugs (G. Powis and R. A. Prough, Eds.) pp 91-140, Taylor & Francis, London.
108. C. A. Mullen, M. Kilstrup, and R. M. Blaese (1992) Transfer of the bacterial gene for cytosine deaminase to a mammalian cells confers lethal sensitivity to 5-fluorocytosine: A negative selection system. Proc. Natl. Acad. Sci. U.S.A. 89, 33-37.
109. U. Haberkorn, F. Oberdorfer, J. Gebert, I. Morr, K. Haack, K. Weber, M. Lindauer, G. Van Kaik, and H. K. Schackert (1996) Monitoring gene therapy with cytosine deaminase: In vitro studies using tritiated-5-fluorocytosine. J. Nucl. Med. 37, 87-94.
110. B. E. Huber, E. A. Austin, V. C. Good, V. C. Knick, S. Tibbels, and C. A. Richards (1993) In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 53, 4619-4626.
111. B. E. Huber, E. A. Austin, C. A. Richards, S. T. Davis, and S. S. Good (1994) Metabolism of 5-fluorocytidine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: Significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl. Acad. Sci. U.S.A. 91, 8302-8306.
112. A. Ohwada, E. A. Hirschowitz, and R. G. Crystal (1996) Regional delivery of an adenovirus vector containing the Escherichia coli cytosine deaminase gene to provide local activation of 5-fluorocytosine to suppress the growth of colon carcinoma metastatic to liver. Hum. Gene Ther. 7, 1567-1576.
113. N. E. Sladek (1987) In Metabolism and Action of Anti-cancer drugs (G. Powis and R. A. Prough, Eds.) pp 48-89, Taylor & Francis, London.
114. L. Bielicki, G. Voelcker, and H. J. Hohorst (1984) Activated cyclophosphamide: an enzyme-mechanism-based suicide inactivator of DNA polymerase/3′,5′ exonuclease. J. Cancer Res. Clin. Oncol. 107, 195-198.
115. T. A. Connors, P. J. Cox, P. B. Farmer, A. B. Foster, A. M. Gilsenan, and M. Jarman (1974) Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide. Biochem. Pharmacol. 23, 115-129.
116. T. K. H. Chang, G. F. Weber, C. L. Crespi, and D. J. Waxman (1993) Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res. 53, 5629-5637
117. M. X. Wei, T. Tamiya, M. Chase, E. J. Boviatsis. T. K. Chang, N. W. Kowall, F. H. Hochberg, D. J. Waxman, X. O. Breakefield, and E. A. Chiocca (1994) Experimental tumor therapy in mice using the cyclophosphamide-activating cytochrome P450-2B1 gene. Hum. Gene Ther. 5, 969-978.
118. J. Halpern, J. Y. Jaw, L. J. Cornfield, C. Balfour, and E. Mash (1989) Selective inactivation of rat liver cytochromes P450 by 21-chlorinated steroids. Drug Metab. Disp. 17, 26-31.
119. M. A. Correia, K. Yao, S. A. Wrighton, D. J. Waxman, and A. E. Rettie (1992) Differential apoprotein loss of rat liver cytochromes P450 after their inactivation by 3,5-dicarbethoxy-2,6-dimethyl-4-ethyl-1,4-dihydropyridine: a case for distinct proteolytic mechanism. Arch. Biochem. Biophys. 294, 493-503.
120. Y. Manome, P. Y. Wen, L. Chen, T. Tanaka, Y. Dong, M. Yamazoe, A. Hirshowitz, D. W. Kufe, and H. A. Fine (1996) Gene therapy for malignant gliomas using replication incompetent retroviral and adenoviral vectors encoding the cytochrome P-450 2B1 gene together with cyclophosphamide. Gene Ther. 3, 513-520.
121. L. Chen, D. J. Waxman, D. Chen, and D. C. Kufe (1996) Sensitization of human breast cancer cells to cyclophosphamide and ifosfamide by transfer of a liver cytochrome P-450 gene. Cancer Res. 56, 1331-1340.
122. T. P. Zimmerman, N. B. Gersten, A. F. Ross, and R. P. Miech (1971) Adenine as substrate for purine nucleoside phosphorylase. Can. J. Biochem. 49, 1050-1054.
123. E. J. Sorscher, S. Peng, Z. Bebok, P. W. Allan, L. L. Bennett Jr., and W. B. Parker (1994) Tumor cell bystander killing in colonic carcinoma utilizing the Escherichia coli deo-D gene to generate toxic purines. Gene Ther. 1, 233-238.
124. A. V. Patterson, H. Zhang, A. Moghaddam, R. Bicknell, D. C. Talbot, I. J. Stratford, and A. L. Harris (1995) Increased sensitivity to the prodrug 5′-deoxy-5-fluorouridine and modulation of 5-fluoro-2′-deoxyuridine sensitivity in MCF-7 cells transfected with thymidine phosphorylase. Br. J. Cancer 72, 669-675.
125. D. M. Hapke, A. P. A. Stegmann, and B. S. Mitchell (1996) Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. Cancer Res. 56, 2343-2347.
126. Y. Manome, P. Y. Wen, Y. Dong, T. Tanaka, B. S. Mitchell, D. W. Kufe, and H. A. Fine (1996) Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat. Med. 2, 567-573.
127. R. F. Sherwood, R. G. Melton, S. M. Alwan, and P. Hughes (1985) Purification and properties of carboxypeptidase G2 Pseudonomas sp strain RS-16. Ear. J. Biochem. 148, 447-453.
128. C. J. Springer, P. Antoniw, K. D. Bagshawe, F. Searle, G. M. F. Bisset, and M. Jarman (1990) Novel prodrugs which are activated to cytotoxic alkylating agents by carboxypeptidase G2. J. Med. Chem. 33, 677-681.
129. R. Dowell, C. J. Springer, D. H. Davies, E. M. Hadley, P. J. Burke, F. T. Boyle, R. G. Melton, T. A. Connors, D. C. Blakey, and A. B. Mauger (1996) New mustard prodrugs for antibody-directed enzyme prodrug therapy: Alternative for the amide link. J. Med. Chem. 39, 1100-1105.
130. C. J. Springer, R. Dowell, P. J. Burke, E. Hadley, D. H. Davies, D. C. Blakey, R. G. Melton, and I. Niculescu-Duvaz (1995) Optimization of alkylating agent prodrugs derived from phenol and aniline mustards: A new clinical candidate prodrug (ZD2767) for antibody-directed enzyme prodrug therapy (ADEPT). J. Med. Chem. 38, 5051-5065.
131. A. C. Khan and W. C. J. Ross (1967) Tumour growth inhibitory nitrophenylaziridines and related compounds: structure activity relationships. Chem. Biol. Interact. 1, 27-47.
132. R. J. Knox, M. P. Boland, F. Friedlos, B. Coles, C. Southan, and J. J. Roberts (1988) The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol 44, 2297-2301.
133. R. J. Knox, F. Friedlos, R. F. Sherwood, R. G. Melton, and G. M. Anlezark (1992) The bioactivation of 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954). II. A comparison of an Escherichia coli nitroreductase and Walker DT-diaphorase. Biochem. Pharmacol. 44, 2297-2301.
134. M. P. Boland, R. J. Knox, and J. J. Roberts (1991) The differences in kinetics of rat and human DT-diaphorase result in in a differential sensitivity of cells lines to CB 1954 [5-(aziridin-1-yl)-2,4-dinitrobenzamide. Biochem. Pharmacol. 41, 867-875.
135. R. C. Mulligan and P. Berg (1981) Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase. Proc. Natl. Acad. Sci. U.S.A. 78, 22072-22076.
136. T. Tamiya, Y. Ono, M. X. Wei, P. J. Mroz, F. L. Moolten, and E. A. Chiocca (1996) Escherichia coli gpt gene sensitizes rat glioma cells to killing by 6-thioxanthine or 6-thioguanine. Cancer Gene Ther. 3, 155-162.
137. A. R. Kinsella, D. Smith, and M. Pickard (1997) Resistance to chemotherapeutic antimetabolites: a function of salvage pathway involvement and cellular response to DNA damage. Br. J. Cancer 75, 935-945.
138. L. Chen and D. J. Waxman (1995) Intratumoral activation and enhanced chemotherapeutic effect of oxazaphosphorines following cytochrome P-450 gene transfer: Development of a combined chemotherapy/cancer gene therapy strategy. Cancer Res. 55, 581-589.
139. P. T. Golumbek, F. M. Hamzeh, E. M. Jaffee, H. Levitsky, P. S. Lietman, and D. M. Pardoll (1992) Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumour cell vaccines. J. Immunother. 12, 224-230.
140. B. A. Teicher and E. Frei III (1988) Development of alkylating agent resistant human tumor cell lines. Cancer Chemother. Pharmacol. 21, 292-298.
141. E. Frei, B. A. Teicher, and S. A. Holden (1988) Preclinical studies and and clinical correlation of the effect of alkylating drugs. Cancer Res. 48, 6417.
142. S. M. Freeman, C. N. Abboud, K. A. Whartenby, C. H. Packman, D. S. Koeplin, F. S. Moolten, and G. N. Abraham (1993) The "bystander effect": Tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res. 53, 5274-5283.
143. Q. T. Trinh, E. A. Austin, D. M. Murray, V. C. Knick, and B. E. Huber (1995) Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug system in a human colorectal cacinoma cell line. Cancer Res. 55, 4808-4812.
144. G. Goldberg and J. S. Bertram (1994) Correspondence re: Z. Ram et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88; (1993) Cancer Res. 54, 3947-3948.
145. G. Goldberg and J. S. Bertram (1994) Correspondence re: Z. Ram et al. In situ retroviral-mediated gene transfer for the treatment of brain tumors in rats. Cancer Res. 53, 83-88; (1993) Cancer Res. 54, 3947-3948.
146. S. F. Dagher, S. E. Conrad, E. A. Werner, and R. J. Patterson (1992) Phenotypic conversion of TK-defficient cells following electroporation of functional TK enzyme. Exp. Cell Res. 198, 36-42.
147. W. L. Bi, L. M. Parysek, R. Warnick, and P. J. Stambrook (1993) In vitro evidence that metabolic cooperation is responsible for the bystander effect observed with HSV tk retroviral gene therapy. Hum. Gene Ther. 4, 725-731.
148. J. Fick, F. G. Barker, P. Dazin, E. M. Westphale, E. C. Beyer, and M. A. Israel (1995) The extent of heterocellular communication mediated gap junctions is predictive of bystander tumor cytotoxicity in vitro. Proc. Natl. Acad. Sci. U.S.A. 92, 11071-11075.
149. S. M. Freeman, R. Ramesh, M. Sastri, A. Munnshi, A. K. Jensen, and A. J. Marrogi (1995) The role of cytokines in mediating the bystander effect using HSV-TK xenogeneic cells. Cancer Lett. 92, 167-174.
150. W. Hamel, L. Magnelli, V. P. Chiarugi, and M. A. Israel (1996) Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res. 56, 2697-2702.
151. R. Ramesh, A. J. Marrogi, A. Munshi, C. N. Abboud, and S. M. Freeman (1996) In vivo analysis of the "bystander effect": A cytokine cascade. Exp. Hematol. 24, 829-838.
152. J. Pavlovic, M. Nawrath, R. Tu, T. Heinicke, and K. Moelling (1996) Anti-tumor immunity is involved in the thymidine kinase-mediated killing of tumors induced by activated Ki-ras (G12V). Gene Ther. 3, 635-643.
153. R. Vile, N. Miller, Y. Chernayovsky, and I. Hart (1994) A comparison of the properties of different retroviral vectors containing the murine tyrosinase promoter to achieve transcriptionally targeted expression of the HSVtk or IL-2 genes. Gene Ther. 1, 307-316.
154. S. H. Chen, X. L. Li Chen, Y. Wang, K. Kosai, M. J. Finegold, S. S. Rich,
155. S. H. Chen, K. Kosai, B. Xu, K. Pham-Nguyen, C. Contant, M. J. Finegold, and S. L. C. Woo (1996) Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: Sustained antitumor immunity prolongs animal survival. Cancer Res. 56, 3758-3762.
156. B. W. O'Malley, K. A. Cope, S. H. Chen, D. Li, M. R. Schwartz, and S. L. C. Woo (1996) Combination gene therapy for oral cancer in a murine model. Cancer Res. 56, 1737-1741.